What is Zacks Research’s Forecast for ESPR FY2025 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a note issued to investors on Thursday, November 28th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings of $0.06 per share for the year, down from their previous estimate of $0.09. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.25) per share.

Several other brokerages have also recently weighed in on ESPR. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Wednesday, November 27th. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Needham & Company LLC cut their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th.

Esperion Therapeutics Stock Up 10.7 %

Shares of ESPR stock opened at $3.10 on Monday. The stock has a market capitalization of $610.82 million, a PE ratio of -4.84 and a beta of 0.96. Esperion Therapeutics has a 52 week low of $1.35 and a 52 week high of $3.44. The firm has a 50 day moving average of $2.14 and a two-hundred day moving average of $2.17.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Eaton Financial Holdings Company LLC acquired a new position in Esperion Therapeutics during the 3rd quarter worth approximately $73,000. Barclays PLC raised its stake in shares of Esperion Therapeutics by 99.6% during the 3rd quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 154,509 shares during the last quarter. Geode Capital Management LLC raised its position in Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after acquiring an additional 171,609 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of Esperion Therapeutics during the 3rd quarter worth approximately $606,000. Finally, Anson Funds Management LP acquired a new position in shares of Esperion Therapeutics in the third quarter worth $540,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.